Should I buy CME Group (CME) stock or is it too late?

CME Group · Financials · price $278

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 67% of its targets hit on this sector (498 calls tested). It aims for $270 (-2.9 %), call made on October 6, 2026, maturing on October 6, 2027 (8 d ago).

The 8 reliable analysts $276-0.9 %

The 4 other firms $313+12 %

How to read it: the 8 reliable firms are not filtered by optimism — 4 aim above the price, 4 below, hence their $276 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on CME Group

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	89 %	+22.1 %	9	$295 +6%
Deutsche Bank	69 %	+12.8 %	29	$270 -3%
Barclays	88 %	+11.6 %	8	$281 +1%
Citigroup	72 %	+10.9 %	18	$300 +8%
UBS	75 %	+8.1 %	16	$270 -3%
B of A Securities	33 %	-3.8 %	6	$230 -17%
Raymond James	29 %	-9.0 %	7	$320 +15%
JP Morgan	33 %	-11.2 %	12	$250 -10%

In short — Should you invest in CME Group? Is it too late, still worth it? Analysts are split (54% buy, median target $298, i.e. +7%), and the most reliable on CME targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on CME, Wells Fargo (100% hit rate, 2 scored calls), targets $301 (call made on October 2, 2026, maturing on October 2, 2027) (+8%) in its most recent call.
Pays a dividend (4.9% yield), raised for 6 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 4 are neutral and 2 are sells.
Limited upside: the median target is only +7% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CME

Median target $298 (+7%) · 13 ratings · Hold consensus

Strong Buy00%

Buy754%

Hold431%

Sell215%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in CME Group now?

We won't decide for you. The facts: 54% of analysts rate it a buy, median target $298 (+7%), and Wells Fargo (most reliable on CME, 100%) targets $301. Weigh that against valuation (P/E ~23). This is not personalized advice.

Is it too late to invest in CME Group?

Not according to analysts: the median target ($298) is still +7% above the current price ($278) (most reliable on CME: Wells Fargo, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is CME Group still worth investing in?

It depends on the gap between the price ($278) and its estimated value: analysts target $298 on median (+7%), with 54% buys (most reliable on CME: Wells Fargo, 100%). Cross-check with their real reliability on CME and the cautions above. Information, not advice.

What's the main risk in buying CME?

The consensus is not unanimous: of 13 ratings, 4 are neutral and 2 are sells.

→ Go deeper: the full CME Group profile (consensus, analyst reliability, price target, performance).